tldrdailynews.com logo

Eli Lilly Stock Declines Amid Disappointment in Obesity Pill Trials

1 min read
Source: TipRanks
Eli Lilly Stock Declines Amid Disappointment in Obesity Pill Trials
Photo: TipRanks
TL;DR

Eli Lilly's stock (LLY) continues to decline as investor enthusiasm for its obesity medication wanes, reflecting changing market dynamics and investor sentiment.

Topics:business#business#eli-lilly#lly#market#obesity-pill#stock
Share this article
  1. Eli Lilly Stock (LLY) Continues to Sink as Enthusiasm for Obesity Pill Fades  TipRanks
  2. Pill Causes Major Weight Loss in Eli Lilly Trial’s Results  The New York Times
  3. Novo Soars as Lilly’s Obesity Pill Disappointment Offers Relief  Bloomberg.com
  4. Eli Lilly Stock Falls Again. Is This Its Novo Nordisk Moment?  Barron's
  5. We're downgrading Lilly and asking ourselves tough questions after its obesity pill letdown  CNBC

Want the full story? Read the original reporting

Read on TipRanks